GB201804860D0 - CD47 Binding agents - Google Patents

CD47 Binding agents

Info

Publication number
GB201804860D0
GB201804860D0 GBGB1804860.3A GB201804860A GB201804860D0 GB 201804860 D0 GB201804860 D0 GB 201804860D0 GB 201804860 A GB201804860 A GB 201804860A GB 201804860 D0 GB201804860 D0 GB 201804860D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
binding
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1804860.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultrahuman Two Ltd
Original Assignee
Ultrahuman Two Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrahuman Two Ltd filed Critical Ultrahuman Two Ltd
Priority to GBGB1804860.3A priority Critical patent/GB201804860D0/en
Publication of GB201804860D0 publication Critical patent/GB201804860D0/en
Priority to GBGB1813693.7A priority patent/GB201813693D0/en
Priority to IL277343A priority patent/IL277343B1/en
Priority to KR1020267004860A priority patent/KR20260036010A/ko
Priority to SG11202008965SA priority patent/SG11202008965SA/en
Priority to CA3093777A priority patent/CA3093777A1/en
Priority to AU2019246401A priority patent/AU2019246401B2/en
Priority to JP2020552716A priority patent/JP7458569B2/ja
Priority to PCT/EP2019/057723 priority patent/WO2019185717A1/en
Priority to US17/041,100 priority patent/US12421310B2/en
Priority to EP19715427.1A priority patent/EP3774886A1/en
Priority to CN201980021901.XA priority patent/CN111936515B/zh
Priority to KR1020207029435A priority patent/KR102929571B1/ko
Priority to US19/192,994 priority patent/US20260015420A1/en
Priority to AU2026200633A priority patent/AU2026200633A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1804860.3A 2018-03-27 2018-03-27 CD47 Binding agents Ceased GB201804860D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1804860.3A GB201804860D0 (en) 2018-03-27 2018-03-27 CD47 Binding agents
GBGB1813693.7A GB201813693D0 (en) 2018-03-27 2018-08-22 CD47 binding agents
KR1020207029435A KR102929571B1 (ko) 2018-03-27 2019-03-27 Cd47 결합제
AU2019246401A AU2019246401B2 (en) 2018-03-27 2019-03-27 CD47 binding agents
US17/041,100 US12421310B2 (en) 2018-03-27 2019-03-27 CD47 binding agents
SG11202008965SA SG11202008965SA (en) 2018-03-27 2019-03-27 Cd47 binding agents
CA3093777A CA3093777A1 (en) 2018-03-27 2019-03-27 Cd47 binding agents
IL277343A IL277343B1 (en) 2018-03-27 2019-03-27 "CD47-binding factors and their uses in the treatment of diseases"
JP2020552716A JP7458569B2 (ja) 2018-03-27 2019-03-27 Ｃｄ４７結合剤
PCT/EP2019/057723 WO2019185717A1 (en) 2018-03-27 2019-03-27 Cd47 binding agents
KR1020267004860A KR20260036010A (ko) 2018-03-27 2019-03-27 Cd47 결합제
EP19715427.1A EP3774886A1 (en) 2018-03-27 2019-03-27 Cd47 binding agents
CN201980021901.XA CN111936515B (zh) 2018-03-27 2019-03-27 Cd47结合剂
US19/192,994 US20260015420A1 (en) 2018-03-27 2025-04-29 Cd47 binding agents
AU2026200633A AU2026200633A1 (en) 2018-03-27 2026-01-29 Cd47 binding agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1804860.3A GB201804860D0 (en) 2018-03-27 2018-03-27 CD47 Binding agents

Publications (1)

Publication Number Publication Date
GB201804860D0 true GB201804860D0 (en) 2018-05-09

Family

ID=62068079

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1804860.3A Ceased GB201804860D0 (en) 2018-03-27 2018-03-27 CD47 Binding agents
GBGB1813693.7A Ceased GB201813693D0 (en) 2018-03-27 2018-08-22 CD47 binding agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB1813693.7A Ceased GB201813693D0 (en) 2018-03-27 2018-08-22 CD47 binding agents

Country Status (11)

Country Link
US (2) US12421310B2 (https=)
EP (1) EP3774886A1 (https=)
JP (1) JP7458569B2 (https=)
KR (2) KR102929571B1 (https=)
CN (1) CN111936515B (https=)
AU (2) AU2019246401B2 (https=)
CA (1) CA3093777A1 (https=)
GB (2) GB201804860D0 (https=)
IL (1) IL277343B1 (https=)
SG (1) SG11202008965SA (https=)
WO (1) WO2019185717A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668897B1 (en) 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4637749B2 (ja) 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN101231382B (zh) 2008-02-26 2010-09-01 上海激光等离子体研究所 用于啁啾脉冲放大的光谱调制整形装置
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
CA2967379A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
BR112018005322A2 (pt) * 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
EP3747906A1 (en) * 2016-01-11 2020-12-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
AU2017250809B2 (en) 2016-04-15 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
EP3668897B1 (en) 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents

Also Published As

Publication number Publication date
US20210179711A1 (en) 2021-06-17
AU2026200633A1 (en) 2026-02-19
IL277343A (en) 2020-10-29
AU2019246401A1 (en) 2020-11-05
US20260015420A1 (en) 2026-01-15
JP7458569B2 (ja) 2024-04-01
EP3774886A1 (en) 2021-02-17
IL277343B1 (en) 2026-04-01
CN111936515B (zh) 2024-04-19
WO2019185717A1 (en) 2019-10-03
US12421310B2 (en) 2025-09-23
KR20260036010A (ko) 2026-03-13
GB201813693D0 (en) 2018-10-03
KR20200136424A (ko) 2020-12-07
SG11202008965SA (en) 2020-10-29
KR102929571B1 (ko) 2026-02-23
AU2019246401B2 (en) 2025-11-06
CN111936515A (zh) 2020-11-13
CA3093777A1 (en) 2019-10-03
JP2021519100A (ja) 2021-08-10

Similar Documents

Publication Publication Date Title
IL277343A (en) CD47 binding factors
IL272643A (en) Binders
GB201802201D0 (en) Binding agents
IL278888A (en) PSMA binding agents and their uses
SG11202103773TA (en) Binding domain
IL268288A (en) Binders
GB201912882D0 (en) Ssea-4 binding members
GB201804094D0 (en) ERBB3 Binding agents
IL276914A (en) CSF1R binding factors
ZA202200734B (en) Binding members
GB201912657D0 (en) Binding members
CA185827S (en) Book
GB201808570D0 (en) Binding agents
GB201802595D0 (en) Binding agents
GB201900555D0 (en) Concept one
GB201820913D0 (en) St
GB201713298D0 (en) Binding agents
GB201713296D0 (en) Binding agents
GB201813992D0 (en) St
HK40010439A (en) Binding agents
GB201813486D0 (en) st
GB201813476D0 (en) st
GB201813347D0 (en) St
GB201813206D0 (en) St
GB201811251D0 (en) St

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)